Sort
15,842 grants matching “pancreatic cancer”
Branched chain amino acids and pancreatic cancer
$463,725Kathryn Elaine Wellen · University Of Pennsylvania · R01 · FY2020 · CA
Ras-mediated signals in human epithelial cell transformation and metastasis
$463,709Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
$463,697Matthew T. Moyer · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2018 · CA
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies
$463,686Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
The Stanford Clinical Center for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
$463,641Walter Gwang-Up Park · Stanford University · U01 · FY2021 · DK
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
$463,556Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER
$463,532Sunil R Hingorani · University Of Nebraska Medical Center · R01 · FY2025 · CA
Project 2 NF-#B regulation in muscle wasting and pancreatic cancer-induced cachexia
$463,387Denis C Guttridge · Medical University Of South Carolina · P01 · FY2023 · CA
Cell Growth Signaling in Cancer Development
$463,125David M Sabatini · Whitehead Institute For Biomedical Res · R01 · FY2018 · CA
Cell Growth Signaling in Cancer Development
$463,125David M Sabatini · Whitehead Institute For Biomedical Res · R01 · FY2020 · CA
Cell Growth Signaling in Cancer Development
$463,125Jonathan S. Weissman · Whitehead Institute For Biomedical Res · R01 · FY2021 · CA
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatment
$463,057Dai Fukumura · Massachusetts General Hospital · R01 · FY2019 · CA
Targeting stem-like cells and their niche in pancreatic cancer
$463,044Tuomas Tammela · Sloan-Kettering Inst Can Research · R37 · FY2024 · CA
Project 2: Exploiting Labile Iron Pools for Improving NSCLC Therapy Using Pharmacological Ascorbate
$462,966Douglas Robert Spitz · University Of Iowa · P01 · FY2019 · CA
The Ohio State University Chronic Pancreatitis Diabetes Pancreas Cancer (CPDPC) Clinical Center
$462,902Philip A. Hart · Ohio State University · U01 · FY2021 · DK
The Complement System and Cancer Cachexia
$462,810Andrew Robert Judge · University Of Florida · R01 · FY2024 · AR
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
$462,770Lily Yang · Emory University · R01 · FY2023 · CA
Stroma penetrating and immune modulating nanoparticles for image-guided therapy of pancreatic cancer
$462,770Lily Yang · Emory University · R01 · FY2022 · CA
Mechanisms that Couple Chromatin Modifications to Transcription
$462,740Karen M Arndt · University Of Pittsburgh At Pittsburgh · R35 · FY2024 · GM
Mechanisms that Couple Chromatin Modifications to Transcription
$462,740Karen M Arndt · University Of Pittsburgh At Pittsburgh · R35 · FY2025 · GM
Mechanisms that Couple Chromatin Modifications to Transcription
$462,740Karen M Arndt · University Of Pittsburgh At Pittsburgh · R35 · FY2023 · GM
Tumor maintenance and development in mouse models
$462,696Harold E Varmus · Sloan-Kettering Inst Can Research · U01 · FY2006 · CA
Dysregulation of TGF Beta Action Pancreatic Cancer
$462,645Murray Korc · Dartmouth College · R37 · FY2009 · CA
Defining epigenetic signaling to reshape pancreatic tumor microenvironment
$462,567Jiaqi Shi · University Of Michigan At Ann Arbor · R37 · FY2022 · CA
A Fragment-Based Strategy for K-RAS Covalent Inhibitors
$462,460Samy Meroueh · University Of Illinois At Urbana-Champaign · R01 · FY2024 · CA